SEC Tracker
Get the app

ReShape Lifesciences HIND

ReShape Lifesciences Q1 FY24: revenue $1.9M; diluted EPS −$7,694.94

Form
10-Q
Filed
Period
Importance
Notable
Document
10-Q

Key figures from this report

These are the numbers ReShape Lifesciences reported for Q1 FY24, the quarter ended Mar 31, 2024, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$1.9MNo year-earlier figure tagged10-Q income statement, on EDGAR
  2. Net income−$2.2MNo year-earlier figure tagged10-Q income statement, on EDGAR
  3. Diluted EPS−$7,694.94No year-earlier figure tagged. Split-adjusted, as the tables show it; the filing reported −$0.0910-Q income statement, on EDGAR
  4. Cash and cash equivalents$2.4MNo year-earlier figure tagged10-Q balance sheet, on EDGAR
  5. Cash from operations−$2.1MNo year-earlier figure tagged10-Q cash flow statement, on EDGAR

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when ReShape Lifesciences files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. AIM ImmunoTech AIM public float $6M, Jun 30, 2025
  2. Adial Pharmaceuticals ADIL public float $6M, Jun 30, 2025
  3. PharmaCyte Biotech PMCB public float $6M, Oct 31, 2025
  4. Natural Alternatives International NAII public float $6M, Dec 31, 2025
  5. LFTD Partners LIFD public float $6M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.